Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant posts strong third quarter

This article was originally published in Clinica

Executive Summary

Cardiac rhythm management sales growth outpaced Guidant's total sales increase in the third quarter with a 20% rise to $119.3 million compared with last year. Strong demand for the Ventak PrxIII AICD implantable defibrillator and the new line of Vigor adaptive rate pacemakers in both the US and Europe led cardiac rhythm sales. The business sector contributed 46% of Guidant's third quarter sales which rose 8% to $234.1 million. Net income grew 8% to $28.0 million.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT093755

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel